<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Liu M</submitter><funding>Ganzhou Key Laboratory of Thyroid Tumors</funding><funding>Project of Science and Technology Program of Jiangxi Province Chinese Medicine for 2023</funding><funding>The National Natural Science Foundation of China</funding><pagination>870</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12076972</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Anaplastic thyroid cancer (ATC) is a markedly invasive subtype of thyroid cancer with a poor prognosis. The Gynostemma pentaphyllum-derived Gypenoside LI (Gyp LI) can inhibit the growth and metastasis of various tumors. This study was designed to evaluate the pharmacological mechanisms of Gyp LI against ATC via network pharmacology analysis combined with experimental verification.&lt;h4>Methods&lt;/h4>Core targets and signaling pathways were obtained by using the network pharmacological analysis method. Utilizing a combination of in vitro and in vivo methodologies, we conducted a rigorous examination to ascertain the suppressive impact of Gyp LI on the ATC cell lines, specifically 8305 C and C643. Then used western blotting and immunohistochemistry to analyze the inhibitory ef</pubmed_abstract><journal>BMC cancer</journal><pubmed_title>Comprehensive network pharmacology and experimentation to unveil the therapeutic efficacy and mechanisms of gypenoside LI in anaplastic thyroid cancer.</pubmed_title><pmcid>PMC12076972</pmcid><funding_grant_id>20220101-24</funding_grant_id><funding_grant_id>2023B0202</funding_grant_id><funding_grant_id>82460498</funding_grant_id><pubmed_authors>Dai M</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Xie Y</pubmed_authors><pubmed_authors>Liu M</pubmed_authors><pubmed_authors>Huang J</pubmed_authors><pubmed_authors>Liao H</pubmed_authors><pubmed_authors>Ying Y</pubmed_authors><pubmed_authors>Peng Q</pubmed_authors><pubmed_authors>Zeng X</pubmed_authors><pubmed_authors>Liu W</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comprehensive network pharmacology and experimentation to unveil the therapeutic efficacy and mechanisms of gypenoside LI in anaplastic thyroid cancer.</name><description>&lt;h4>Background&lt;/h4>Anaplastic thyroid cancer (ATC) is a markedly invasive subtype of thyroid cancer with a poor prognosis. The Gynostemma pentaphyllum-derived Gypenoside LI (Gyp LI) can inhibit the growth and metastasis of various tumors. This study was designed to evaluate the pharmacological mechanisms of Gyp LI against ATC via network pharmacology analysis combined with experimental verification.&lt;h4>Methods&lt;/h4>Core targets and signaling pathways were obtained by using the network pharmacological analysis method. Utilizing a combination of in vitro and in vivo methodologies, we conducted a rigorous examination to ascertain the suppressive impact of Gyp LI on the ATC cell lines, specifically 8305 C and C643. Then used western blotting and immunohistochemistry to analyze the inhibitory ef</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 May</publication><modification>2026-05-19T03:15:55.768Z</modification><creation>2026-05-19T03:07:13.723Z</creation></dates><accession>S-EPMC12076972</accession><cross_references><pubmed>40369482</pubmed><doi>10.1186/s12885-025-14231-8</doi></cross_references></HashMap>